These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 10565020)

  • 1. Antisense oligonucleotides: preparation and in vivo application to rat brain.
    Tischmeyer W
    Methods Enzymol; 2000; 314():275-90. PubMed ID: 10565020
    [No Abstract]   [Full Text] [Related]  

  • 2. Strategies for the design and delivery of antisense oligonucleotides in central nervous system.
    Broaddus WC; Prabhu SS; Wu-Pong S; Gillies GT; Fillmore H
    Methods Enzymol; 2000; 314():121-35. PubMed ID: 10565009
    [No Abstract]   [Full Text] [Related]  

  • 3. Effects of antisense oligonucleotides on brain delta-opioid receptor density and on SNC80-induced locomotor stimulation and colonic transit inhibition in rats.
    Negri L; Broccardo M; Lattanzi R; Melchiorri P
    Br J Pharmacol; 1999 Dec; 128(7):1554-60. PubMed ID: 10602336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro and in vivo effects of antisense on alpha 2-adrenoceptor expression.
    Robinson ES; Hudson AL
    Methods Enzymol; 2000; 314():61-76. PubMed ID: 10565005
    [No Abstract]   [Full Text] [Related]  

  • 5. Potent and nontoxic antisense oligonucleotides containing locked nucleic acids.
    Wahlestedt C; Salmi P; Good L; Kela J; Johnsson T; Hökfelt T; Broberger C; Porreca F; Lai J; Ren K; Ossipov M; Koshkin A; Jakobsen N; Skouv J; Oerum H; Jacobsen MH; Wengel J
    Proc Natl Acad Sci U S A; 2000 May; 97(10):5633-8. PubMed ID: 10805816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting brain GABAA receptors with antisense oligonucleotides: implications for epilepsy.
    Karle J; Nielsen M
    Methods Enzymol; 2000; 314():20-32. PubMed ID: 10565002
    [No Abstract]   [Full Text] [Related]  

  • 7. Progress in antisense technology: the end of the beginning.
    Crooke ST
    Methods Enzymol; 2000; 313():3-45. PubMed ID: 10595347
    [No Abstract]   [Full Text] [Related]  

  • 8. Use of minimally modified antisense oligonucleotides for specific inhibition of gene expression.
    Uhlmann E; Peyman A; Ryte A; Schmidt A; Buddecke E
    Methods Enzymol; 2000; 313():268-84. PubMed ID: 10595361
    [No Abstract]   [Full Text] [Related]  

  • 9. Antisense oligodeoxynucleotides as a tool in developmental neuroendocrinology.
    McCarthy MM; Auger AP; Mong JA; Sickel MJ; Davis AM
    Methods; 2000 Nov; 22(3):239-48. PubMed ID: 11071819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The uptake of a fluorescently labelled antisense oligonucleotide in vitro and in vivo.
    Robinson ES; Nutt DJ; Jackson HC; Hudson AL
    J Neurosci Methods; 2005 Aug; 147(1):48-54. PubMed ID: 16054515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Attenuation of alpha2A-adrenergic receptor expression in neonatal rat brain by RNA interference or antisense oligonucleotide reduced anxiety in adulthood.
    Shishkina GT; Kalinina TS; Dygalo NN
    Neuroscience; 2004; 129(3):521-8. PubMed ID: 15541874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro and in vivo modulation of transforming growth factor beta 1 gene expression by antisense oligomer.
    Chung HT; Sohn DH; Choi BM; Yoo JC; Pae HO; Jun CD
    Methods Enzymol; 2000; 314():493-9. PubMed ID: 10565034
    [No Abstract]   [Full Text] [Related]  

  • 13. Application of antisense oligodeoxynucleotides in developing chick embryos.
    Alexander PG; Barnes GL; Tuan RS
    Methods Mol Biol; 2000; 137():23-36. PubMed ID: 10948522
    [No Abstract]   [Full Text] [Related]  

  • 14. Determination of cellular internalization of fluoresceinated oligonucleotides.
    Benimetskaya L; Tonkinson J; Stein CA
    Methods Enzymol; 2000; 313():287-97. PubMed ID: 10595362
    [No Abstract]   [Full Text] [Related]  

  • 15. Design of antisense and triplex-forming oligonucleotides.
    François JC; Lacoste J; Lacroix L; Mergny JL
    Methods Enzymol; 2000; 313():74-95. PubMed ID: 10595350
    [No Abstract]   [Full Text] [Related]  

  • 16. Evidence for sequence-dependent and reversible nonspecific effects of PS-capped antisense treatment after intracerebral administration.
    Boye SM; Pradhan AA; Grant RJ; Clarke PB
    Antisense Nucleic Acid Drug Dev; 2002 Apr; 12(2):95-102. PubMed ID: 12074369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antisense approach for study of cell adhesion molecules in central nervous system.
    Mileusnic R
    Methods Enzymol; 2000; 314():213-23. PubMed ID: 10565015
    [No Abstract]   [Full Text] [Related]  

  • 18. Technology evaluation: ISIS-3521.
    Li K; Zhang J; Sirois P; Hu Y
    Curr Opin Mol Ther; 1999 Jun; 1(3):393-8. PubMed ID: 11713804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and efficacy of serotonin-2A receptor antisense oligodeoxynucleotide.
    Scalzitti JM; Hensler JG
    Methods Enzymol; 2000; 314():76-89. PubMed ID: 10565006
    [No Abstract]   [Full Text] [Related]  

  • 20. In vitro transport and delivery of antisense oligonucleotides.
    Hughes J; Astriab A; Yoo H; Alahari S; Liang E; Sergueev D; Shaw BR; Juliano RL
    Methods Enzymol; 2000; 313():342-58. PubMed ID: 10595365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.